Hls Therapeutics Stock Today
| HLS Stock | CAD 4.40 0.27 6.54% |
PerformanceOK
| Odds Of DistressLow
|
HLS Therapeutics is selling at 4.40 as of the 19th of March 2025; that is 6.54 percent increase since the beginning of the trading day. The stock's open price was 4.13. HLS Therapeutics has less than a 17 % chance of experiencing some financial distress in the next two years of operation, but did not have a good performance during the last 90 trading days. The performance scores are derived for the period starting the 19th of December 2024 and ending today, the 19th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | Category Healthcare | Classification Health Care |
HLS Therapeutics Inc., a specialty pharmaceutical company, focuses on acquiring and commercializing pharmaceutical products in the specialty central nervous system and cardiovascular markets. It has license agreement with Amarin Corporation plc to register, commercialize, and distribute Vascepa capsules in Canada. The company has 31.79 M outstanding shares of which 33.01 K shares are currently shorted by private and institutional investors with about 1.98 days to cover all short positions. More on HLS Therapeutics
Moving against HLS Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
HLS Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. HLS Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding HLS Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO Director | Craig MBA | ||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Pharmaceuticals, Drug Manufacturers - Specialty & Generic, Healthcare (View all Sectors) | ||||
HLS Therapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to HLS Therapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Debt LevelsHLS Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand HLS Therapeutics' financial leverage. It provides some insight into what part of HLS Therapeutics' total assets is financed by creditors.
| |||||
HLS Therapeutics (HLS) is traded on Toronto Exchange in Canada and employs 12 people. HLS Therapeutics is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 131.31 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate HLS Therapeutics's market, we take the total number of its shares issued and multiply it by HLS Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. HLS Therapeutics operates under Pharmaceuticals sector and is part of Health Care industry. The entity has 31.79 M outstanding shares of which 33.01 K shares are currently shorted by private and institutional investors with about 1.98 days to cover all short positions.
HLS Therapeutics has accumulated about 20.72 M in cash with 8 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.7.
Check HLS Therapeutics Probability Of Bankruptcy
Ownership AllocationHLS Therapeutics has a total of 31.79 Million outstanding shares. Over half of HLS Therapeutics' outstanding shares are owned by outside corporations. These outside corporations are typically referred to as corporate investors that purchase positions in a given instrument to benefit from reduced trade commissions. Therefore, these institutions are subject to different rules and regulations than regular investors in HLS Therapeutics. Please watch out for any change in the institutional holdings of HLS Therapeutics as this could mean something significant has changed or is about to change at the company. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check HLS Ownership Details
HLS Therapeutics Risk Profiles
Although HLS Therapeutics' alpha and beta are two of the key measurements used to evaluate HLS Therapeutics' performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 1.29 | |||
| Semi Deviation | 1.12 | |||
| Standard Deviation | 1.59 | |||
| Variance | 2.52 |
HLS Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in HLS Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Backtesting Now
Portfolio BacktestingAvoid under-diversification and over-optimization by backtesting your portfolios |
| All Next | Launch Module |
HLS Therapeutics Corporate Management
Elected by the shareholders, the HLS Therapeutics' board of directors comprises two types of representatives: HLS Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of HLS. The board's role is to monitor HLS Therapeutics' management team and ensure that shareholders' interests are well served. HLS Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, HLS Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| BA LLB | CoFounder Chairman | Profile | |
| Brian Walsh | Senior Commercial | Profile | |
| Sanjiv Sharma | Chief Officer | Profile | |
| JD BA | HR Legal | Profile | |
| David Spence | Co Controller | Profile | |
| Jason PharmD | Vice Affairs | Profile |
Other Information on Investing in HLS Stock
HLS Therapeutics financial ratios help investors to determine whether HLS Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in HLS with respect to the benefits of owning HLS Therapeutics security.